Reduction in Airborne Bacterial Levels in OR Supplemental System

OR Air Supplemental System reduced mean bacterial CFU/m³ by 57%.


Environmental risk factors include the presence of airborne viable microorganisms in the OR air, in close proximity to the surgical wound. Bacterial cells can be transported on dust, skin scales, fabric fibers and respiratory or mechanically-generated aerosols. OR air quality should be scrupulously monitored during surgical procedures involving the use of implants. It is well established that contamination of a surgical implant and subsequent development of SSI can occur with a very small bacterial inoculum, eventually, leading to biofilm formation and establishment of a chronic, drug-resistant and costly infection.


In light of recent scientific data there is increased interest in considering innovative supplemental technologies to support best air quality in high risk ORs. This study was designed to test the efficacy of the innovative HEPA/UV-C supplemental ultraclean air system (SUCAS) on reducing airborne bacterial levels in an active orthopedic OR.

Results & Conclusions

To test the efficacy of SUCAS system in reducing airborne bioburden, two arthroplasty operating rooms were selected for evaluation. Overall, presence of SUCAS system reduced mean bacterial CFU/m³ by 57%, the difference is statistically significant, p=0.004.

Reach Us

444 Alexandersville Rd
Miamisburg, Ohio 45342
+1 888 978 7087

Reach Us

350 Fame Road
West Carrollton, Ohio 45449 USA
+1 888 978 7087


President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.


Vice President of Sales

Nathan brings a high level of commitment to servicing and building client relations. He was one of the first employees to start for Aerobiotix. Nathan has previously held leadership roles in the medical device industry. He received his BS from Antioch McGregor University Midwest.


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.